The 'Lead Compound' Rule: Problems and More Problems : vimar

On August 22, 2023, the U.S. Court of Appeals for the Federal Circuit issued yet another decision reinforcing what can only be described as the “lead compound” rule for challenging pharmaceutical and other chemical compound patents on the basis of obviousness.

Related Keywords

Sun Pharm , Otsuka Pharm , Incyte Inc , Hesai Co , Sandoz Inc , Us Court , Teleflex Inc , Depuy Spine Inc , Hindus Inc , Medtronic Sofamor Danek Inc , Intl Co , Gm Global Operations , Matrix Labs Ltd , Spectrum Furniture Co Inc , Co Ltd , Dow Chemical Co , Cochlear Bone Anchored Solutions , Supreme Court , Daiichi Sankyo Co Ltd , Trademark Office , Reddy Labs Ltd , Reliance Universal Inc , Federal Circuit , Lead Compound Rule , Drug Patents Leads Courts Astray , Best Is Not , Lead Compound Is Not , Puy Spine , Sofamor Danek , Prior Art , Universal Inc , Patent Examining Procedures ,